Search

Introduction: Potatoes are one of the world's most important agricultural crops, with potential for making a major contribution to global food security. This study shows how a biostimulant derived from a plant extract can improve potato crop yield and global food supply. Successful potato production currently requires significant levels of inputs including fertiliser, pesticides and irrigation, however non-microbial plant biostimulants or mixtures of biostimulants with synergistic actions, have the capacity to reduce inputs and improve the sustainability of intensive agriculture. Methods: A complex biostimulant containing a number of flavonoids including protocatechuic acid, quercetin, chlorogenic acid, coumaroyl quinic acid and gentistic acid was tested against three potato varieties for its efficacy in improving plant growth characteristics and tuber production in controlled and field environments. Results: In containers, complex biostimulant treatment enhanced photosynthetic ability, with elevated levels of chlorophyll, higher specific leaf areas and significantly larger leaf assimilation areas. Treatment also significantly increased tuber yield by an average of 33% in tuber weight across three potato varieties and shifted tuber production toward larger sized tubers. The biostimulant derived from flavonoids was also assessed in 6 commercial potato crops and consistently increased total yield (average 5.2%) and marketable yield, representing an increase in margins of UK£700 per hectare across the 6 crops. Similar increases in yield were seen when comparing chitted and unchitted seed potatoes and both types of seed responded positively to biostimulant application. Biostimulant treatment had no significant effects on tuber specific gravity, dry matter percentage and starch content, except at one location where these quality characteristics were higher in the control plants. Conclusion: The flavonoid based complex biostimulant produced significant effects on potato yield and quality in both container experiments and in field trials indicating its potential for contributing to sustainable potato production. [ABSTRACT FROM AUTHOR]

The COVID-19 pandemic due to SARS-CoV-2 infection can produce Acute Respiratory Distress Syndrome as a result of a pulmonary cytokine storm. Antihistamines are safe and effective treatments for reducing inflammation and cytokine release. Combinations of Histamine-1 and Histamine-2 receptor antagonists have been effective in urticaria, and might reduce the histamine-mediated pulmonary cytokine storm in COVID-19. Can a combination of Histamine-1 and Histamine-2 receptor blockers improve COVID-19 inpatient outcomes? A physician-sponsored cohort study of cetirizine and famotidine was performed in hospitalized patients with severe to critical pulmonary symptoms. Pulmonologists led the inpatient care in a single medical center of 110 high-acuity patients that were treated with cetirizine 10 mg b.i.d. and famotidine 20 mg b.i.d. plus standard-of-care. Of all patients, including those with Do Not Resuscitate directives, receiving the dual-histamine receptor blockade for at least 48 h, the combination drug treatment resulted in a 16.4% rate of intubation, a 7.3% rate of intubation after a minimum of 48 h of treatment, a 15.5% rate of inpatient mortality, and 11.0 days duration of hospitalization. The drug combination exhibited beneficial reductions in inpatient mortality and symptom progression when compared to published reports of COVID-19 inpatients. Concomitant medications were assessed and hydroxychloroquine was correlated with worse outcomes. This physician-sponsored cohort study of cetirizine and famotidine provides proof-of-concept of a safe and effective method to reduce the progression in symptom severity, presumably by minimizing the histamine-mediated cytokine storm. Further clinical studies in COVID-19 are warranted of the repurposed off-label combination of two historically-safe histamine receptor blockers. [ABSTRACT FROM AUTHOR]